Dyne Therapeutics (DYN) to Announce Quarterly Earnings on Monday

Dyne Therapeutics (NASDAQ:DYN) is anticipated to issue its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 9:30 AM ET.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business earned ($1.05) earnings per share. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dyne Therapeutics Stock Up 2.3%

DYN opened at $24.44 on Friday. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of -7.59 and a beta of 1.06. The firm has a 50 day moving average price of $20.38 and a 200-day moving average price of $18.62. Dyne Therapeutics has a twelve month low of $8.88 and a twelve month high of $25.00. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Insider Buying and Selling at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer owned 121,563 shares in the company, valued at $2,476,238.31. This trade represents a 1.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 297,211 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the sale, the director directly owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. The trade was a 99.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 2,066,372 shares valued at $43,648,928. 9.46% of the stock is owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently bought and sold shares of DYN. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics in the fourth quarter worth about $84,000. Steward Partners Investment Advisory LLC grew its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the period. Verition Fund Management LLC bought a new position in shares of Dyne Therapeutics during the 4th quarter valued at approximately $204,000. Tower Research Capital LLC TRC increased its holdings in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $147,000. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

DYN has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. TD Cowen started coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Cantor Fitzgerald started coverage on Dyne Therapeutics in a report on Thursday. They set an “overweight” rating on the stock. Sanford C. Bernstein raised their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.